MERK's MEVACOR (LOVASTATIN) WILL BE TARGETED AT HYPERCHOLESTEROLEMICS AT HIGH RISK; ADVISORY PANEL RECOMMENDS APPROVAL, FREQUENT LIVER MONITORING